Day: August 7, 2025

Achieved record-high quarterly revenues since inceptionIncreased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2-25 Highlights Financial resultsRevenues were $107,358, an increase of $11,785 or 12% over the same period in prior year. Gross margin was $44,831 or 42% of revenues compared to $47,337 or 50% of revenues in the same period in prior year. The decrease was mainly driven by the impact of the hyperinflation accounting in Argentina. Operating loss was $3,669 compared...

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gravis – – Rese-cel clinical data presented at the EULAR 2025 Congress reinforce compelling clinical responses with nearly all patients off immunomodulatory medications and steroids; favorable risk-benefit profile observed across myositis, lupus and systemic sclerosis patients – – Closed $100 million public offering to support late clinical-stage...

TROY, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the second quarter of 2025.Q2 revenue of $1.1 billion, up 4.2% year-over-year reflecting previously disclosed acquisitions, and down 3.3% on an organic basis Q2 operating earnings of $22.2 million; $24.6 million on an adjusted basis, down 12.1% versus the prior year period Q2 adjusted EBITDA of $37.0 million, down 8.7% versus the prior year; adjusted EBITDA margin decreased 40 basis points (“bps”) to 3.4% Company expects year-over-year revenue decline of 5% to 7% in Q3 driven by reduced demand for U.S. federal contractors and from certain large customers. Adjusted EBITDA margin expansion of 80 to 90 bps is expected in Q3 and modest year-over-year margin improvement for the full...

Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025 SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for second quarter 2025. “This quarter represents a significant step forward for Achieve. After years of focused dedication, we’ve reached the major milestone of submitting our NDA for cytisinicline, established an innovative commercialization partnership with Omnicom, and secured financing to advance our vision,” said Rick Stewart, Chief Executive Officer of Achieve Life Sciences. “By combining our evidenced-based science with an agile,...

Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved alignment with FDA on the design and advancement of Phase 2b SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes (SAFEGUARD) study following a constructive Type B meeting SAFEGUARD study to initiate in Q3 2025 MIAMI, Aug. 07, 2025 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of autoimmune type 1 diabetes (T1D), today announced...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-end Expanding total enrollment of the MAGNITUDE study to approximately 1,200 patients, subject to health authority review, with no expected impact on previous projected enrollment or financial runway Expect to complete enrollment by first half 2026 in the global Phase 3 MAGNITUDE-2 study evaluating nex-z in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) Expect to complete randomization in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) during the third quarter Additional data from the Phase 1/2 study evaluating lonvo-z in HAE and longer-term data from the Phase...

HOUSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology and infrastructure services company, today announced its financial results for the second quarter ended June 30, 2025. Intuitive Machines CEO Steve Altemus said, “We’ve executed decisively in the second quarter. Internally, we’ve brought satellite manufacturing in-house, ensuring performance, schedule clarity, and tight integration with our landers and space systems. Externally, we moved to acquire KinetX, a team that delivers exactly the kind of analysis and real-time decision software that our future network will depend on.” HighlightsSigned purchase agreement to acquire KinetX, an industry leading space navigation and flight dynamics software company, which positions Intuitive...

Second Quarter Revenue of $33.1 Million up 13% YoY (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM and OTCQB: ILLMF) (“illumin” or the “Company”), the advertising technology platform that enables advertisers to see more and achieve more, today announced its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 HighlightsSecond quarter 2025 revenue rose 13% year-over-year to $33.1 million, driven by growth in Exchange service and Self service revenue, partially offset by a decrease in Managed service revenue. Self service revenue was $9.2 million, representing 28% of total revenue and an increase of 5% compared with the year ago period.   The Company onboarded 31 new Self service clients during...

Net revenue in Q2 2025 increased by 21% year-over-year PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Highest-ever international and Israel revenue, fueled by strong global demand Industry-leading balance sheet with $834 million in total cash and cash equivalents and short-term investments TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 second quarter business results. “Cronos delivered another quarter of strong performance, highlighted by record sales from Cronos Israel and continued momentum in international markets. Our strength abroad has been instrumental in driving meaningful margin improvement, underscoring the benefits of our global strategy. Our results in Israel reflect the strong demand...

Second quarter 2025 GAAP net income of $3.4 million or $0.25 per basic weighted average common share and Distributable Earnings(1) of $4.1 million or $0.31 per basic weighted average common share WEST PALM BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (Nasdaq: SUNS) (“SUNS” or the “Company”), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced its results for the quarter ended June 30, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $3.4 million or $0.25 per basic weighted average common share and Distributable Earnings of $4.1 million or $0.31 per basic weighted average common share for the second quarter of 2025. Brian Sedrish, Chief Executive Officer, said, “As market activity rebounds, we’re seeing more transaction volume and increased...